Evidence map›Paper›PMID 36820986›Full record

ArticleCellular and molecular life sciences : CMLS2023

Mfsd2a attenuated hypoxic-ischemic brain damage via protection of the blood-brain barrier in mfat-1 transgenic mice.

Xiaoxue Li, Yumeng Zhang, Jianghao Chang, Chenglin Zhang, Lin Li, Yifan Dai, Haiyuan Yang, Ying Wang

Open access · hybridAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Channels and Transporters in Ischemic Brain Edema.Journal of inflammation research · 2025
    Review
  12. Article
  13. Article
  14. Dietary LPC-BoundNutrients · 2024
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Xiaoxue LiDepartment of Medical Genetics, School of Basic Medical Science, Nanjing Medical University, Nanjing, 211166, China.ORCID http://orcid.org/0000-0002-1158-764X
Yumeng ZhangDepartment of Medical Genetics, School of Basic Medical Science, Nanjing Medical University, Nanjing, 211166, China.
Jianghao ChangDepartment of Medical Genetics, School of Basic Medical Science, Nanjing Medical University, Nanjing, 211166, China.
Chenglin ZhangDepartment of Medical Genetics, School of Basic Medical Science, Nanjing Medical University, Nanjing, 211166, China.
Lin LiDepartment of Medical Genetics, School of Basic Medical Science, Nanjing Medical University, Nanjing, 211166, China.
Yifan DaiDepartment of Medical Genetics, School of Basic Medical Science, Nanjing Medical University, Nanjing, 211166, China. daiyifan@njmu.edu.cn.
Haiyuan YangDepartment of Medical Genetics, School of Basic Medical Science, Nanjing Medical University, Nanjing, 211166, China. hyyang@njmu.edu.cn.
Ying WangDepartment of Medical Genetics, School of Basic Medical Science, Nanjing Medical University, Nanjing, 211166, China. ywang@njmu.edu.cn.
Nanjing Medical University · CNNanjing University of Chinese Medicine · CN

Funding

National Natural Science Foundation of China 81874144National Natural Science Foundation of China 81970164
6 · The paper itself

Abstract

Previous studies have shown that mfat-1 transgenic mice have protective effects against some central nervous system (CNS) disorders, owing to the high docosahexaenoic acid (DHA) content enriched in their brains. However, whether this protective effect is connected to the blood-brain barrier (BBB) remains unclear. This study aims to investigate the mechanisms of the protective effect against hypoxic-ischemic brain damage (HIBD) of mfat-1 transgenic mice. mfat-1 mice not only demonstrated a significant amelioration of neurological dysfunction and neuronal damage but also partly maintained the physiological permeability of the BBB after HIBD. We initially showed this was associated with elevated major facilitator superfamily domain-containing 2a (Mfsd2a) expression on the BBB, resulting from more lysophosphatidylcholine (LPC)-DHA entering the brain. Wild-type (WT) mice showed a similar Mfsd2a expression trend after long-term feeding with an LPC-DHA-rich diet. Knockdown of Mfsd2a by siRNA intra-cerebroventricular (ICV) injection neutralized the protective effect against HIBD-induced BBB disruption in mfat-1 mice, further validating the protective function of Mfsd2a on BBB. HIBD-induced BBB high permeability was attenuated by Mfsd2a, primarily through a transcellular pathway to decrease caveolae-like vesicle-mediated transcytosis. Taken together, these findings not only reveal that mfat-1 transgenic mice have higher expression of Mfsd2a on the BBB, which partly sustains BBB permeability via vesicular transcytosis to alleviate the severity of HIBD, but also suggest that dietary intake of LPC-DHA may upregulate Mfsd2a expression as a novel therapeutic strategy for BBB dysfunction and survival in HIBD patients.

Indexed as

Blood-Brain BarrierHypoxia-Ischemia, BrainSymportersAnimalsBiological TransportBrainDocosahexaenoic AcidsMiceMice, TransgenicDocosahexaenoic AcidsMfsd2a protein, mouseSymportersApoptosisHepatocytesLC–MS/MSNormFinderPLA1TEM

Identifiers

PMID36820986
PMCPMC9950179
OpenAlexW4321612004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.